Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taro Pharmaceutical Industries Ltd.

www.taro.com

Latest From Taro Pharmaceutical Industries Ltd.

Who’s Hired? George and Yanai Join Amneal’s Board

Two familiar industry figures have bolstered Amneal’s board, while Latvia’s Olanfarm has turned to a Sanofi executive for external expertise. Meanwhile, both Taro and Pfenex are recruiting CFOs.

Appointments Leadership

Lupin Adds To US Portfolio

The launch of injectable doxercalciferol and FDA approvals for mycophenolic acid delayed-release tablets and betamethasone dipropionate ointment could add some cheer to Lupin whose high-potential launches in the US have seen delays. However, analysts are not very enthused.

Launches Generic Drugs

Zero Count Adds Up To 70,000-Bottle Ranitidine Recall For AuroMedics

Additional recent recalls include 19,000 bottles of product marketed by Fitoterapia USA and labeled as liquid vitamin C but found to contain erectile dysfunction drug taldalafil .Ongoing testing of ranitidine drugs by FDA and manufacturers led to Aurobindo Pharma USA recall of one lot of OTC 150-mg tablets.

Consumer FDA

Teva And Apotex Fail To Bar Sun And Sandoz From Canadian Rivaroxaban Case

Sandoz and Sun’s Taro can be added to a pending trial over Canadian patents protecting Bayer’s Xarelto cardiovascular drug. Teva and Apotex had sought to be alone in their dispute over the rivaroxaban brand.

Intellectual Property Canada
See All

Company Information

UsernamePublicRestriction

Register